LymphoSign CE-IVD: Workflow and Specifications for NHL Diagnostics
Non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of cancers, characterized by the abnormal proliferation of lymphocytes and encompassing multiple subtypes.
In precision pathology, the LymphoSign CE-IVD Kit provides a reliable solution for NHL classification by enabling accurate identification of over 80 distinct subtypes, supporting refined diagnostic stratification.
Key Features
Designed for integration into standard laboratory workflows, the LymphoSign CE-IVD Kit assesses tumor cell differentiation and accurately classifies B- and T-cell non-Hodgkin lymphomas.
Simple, 4-Step Protocol
Complete RNA-to-result workflow in 24 hours with four streamlined steps: reverse transcription, hybridization, ligation, PCR & sequencing.
Economic, Precise, and Rapid
Requires minimal RNA (50–500 ng), works on FFPE/low-quality samples, no early purification, and targets short sequences (40–60 bases) for reliable performance.
Robust Computer Analysis
RT-MIS software with AI analyzes sequencing data against 3,000+ tumor profiles to classify 13 B-cell and T-cell NHL subtypes.
The LymphoSign CE-IVD Kit combines RT-MLPSeq–based RNA expression profiling of more than 130 gene markers. (Table 1)
Table 1: List of LymphoSign test markers
Technical Highlights
The LymphoSign CE-IVD Kit supports laboratories by enabling improved non-Hodgkin lymphoma subtype discrimination, reducing diagnostic uncertainty, supporting clinical and research decision-making, and facilitating the generation of robust, reproducible molecular data suitable for publication.
Method
Ligation-dependent RT-PCR.
Technology:
Next Generation Sequencing (NGS).
Sample Types
Tissue biopsies (room temperature, frozen, or FFPE).
Equipment Compatible
Illumina MiSeq, NextSeq 500/550.
Handling Duration
≃4 hours.
Actual Working Time
1–1.5 hours.
The LymphoSign CE-IVD Kit is available in multiple reaction formats to suit your laboratory throughput:
| Cat# | Size | |||
| GEP-LS08 | 8 reactions | |||
| GEP-LS16 | 16 reactions | |||
| GEP-LS24 | 24 reactions | |||
| GEP-LS48 | 48 reactions | |||
For additional insights, access the recording of our LymphoSign webinar from the 36th European Congress of Pathology.
Medical Device Notice
These products are medical devices.
Please follow the manufacturer’s instructions.
